Citi lowered the firm’s price target on Madrigal Pharmaceuticals to $371 from $382 and keeps a Buy rating on the shares following the Q2 report. The company highlighted strength across key launch metrics, projecting confidence that they can launch directly in Europe without a partner, the analyst tells investors in a research note. The firm believes Madrigal is well positioned as it ramps Rezdiffra’s launch in the coming quarters and into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals reports Q2 EPS ($7.10), consensus ($7.52)
- Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
- MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
- Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024